Finding new medications to treat Asthma in Overweight adults
Researchers at Vanderbilt University Medical Center are conducting the GATA-3 Clinical Trial for a possible new treatment of Asthma in overweight adults using a weekly injection of Semaglutide, a drug already approved by the FDA for the treatment of obesity and Type 2 Diabetes.
We anticipate that the drug also has a positive effect on asthma symptoms and the airway inflammation caused by persistent asthma.
The full study title is “Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma”; or “GATA-3” for short.
About the Study
Interested participants will undergo screening procedures to determine eligibility. There are several criteria that need to be met prior to study admission.
If you decide to join the study, you will either receive a study drug or something that looks like the study drug but has no medicine (placebo) in it. You will not know if you are receiving the study drug or the placebo drug.
Both groups are crucial to the study in order to find out if getting new drugs are more beneficial than not receiving them.
Joining this study is voluntary and you can choose to stop at any time.
Why is this study important?
Obesity increases the risk of developing asthma and increases asthma severity.
Many of our available treatments for asthma do not work as well in patients with asthma and obesity.
This study will test whether an already approved drug for other medical conditions can improve asthma symptoms and inflammation in the lungs.
What drugs are being studied?
Wegovy, or Semaglutide is an anti-obesity and anti-diabetic drug classified as a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.
Semaglutide can be safely used in patients who are overweight or obese who do not have diabetes.